Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | — | — | — | — |
Altman Z-Score |
— | — | — | — | — | 3.31 | — | — | — | — |
P/S ratio |
— | — | — | — | — | 356.47 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 5.59 | — | — | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | — | — | (40.45) | — | — | — | — |
P/B ratio |
— | — | — | — | — | 1.28 | — | — | — | — |
Price to Tangible BV |
— | — | — | — | — | 1.38 | — | — | — | — |
EV/Sales |
— | — | — | — | — | 66.48 | — | — | — | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | — | — | (0.93) | — | — | — | — |
EV/FCF |
— | — | — | — | — | (0.92) | — | — | — | — |
Quick Ratio |
7.92 | 11.53 | 14.09 | 8.41 | 13.56 | 38.80 | 2.00 | 1.97 | 1.34 | 4.67 |
Current Ratio |
8.10 | 11.77 | 14.26 | 8.59 | 13.89 | 39.50 | 2.50 | 2.05 | 1.42 | 4.76 |
Net Debt/EBITDA |
1.53 | 1.33 | 1.79 | 0.54 | 2.80 | 3.92 | 0.64 | 0.76 | 0.39 | 1.05 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.69% | 7.02% | 5.52% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.20 | 0.06 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.14 | 1.56 | 0.96 | 0.38 | 1.76 | 0.73 | 0.90 | 0.63 | 0.58 | 0.66 |
Capex/Depreciation |
0.00 | 0.00 | (587.73) | (40.58) | — | (0.07) | (0.14) | (0.23) | (0.17) | 0.00 |
Interest Coverage |
— | — | — | (212.01) | (202.45) | (5.04) | (22.73) | (6.94) | (13.45) | (179.36) |
| (11.94%) | (14.91%) | (19.82%) | (48.15%) | (11.98%) | (57.33%) | (212.26%) | (450.89%) | (147.88%) | (47.44%) | |
| (11.24%) | (13.17%) | (16.86%) | (40.85%) | (10.28%) | (46.13%) | (85.40%) | (143.65%) | (90.69%) | (40.36%) | |
ROIC |
(14.76%) | (23.44%) | (20.74%) | (81.36%) | (15.08%) | 0.00% | 0.00% | 0.00% | (763.15%) | 0.00% |
Return on Tangible Assets |
(51.13%) | (46.01%) | (57.51%) | (163.30%) | (23.23%) | (32.32%) | (194.40%) | (239.96%) | (382.91%) | (96.50%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 986.99 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2,129.08% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,399.49% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.74 | 0.68 | 0.67 | 0.62 | 0.64 | 0.00 | 0.19 | 0.17 | 0.44 | 0.49 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 598.98% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | — | — | — | 0.78 | — | — | — | — |
Graham Number |
— | — | — | — | — | 0.00 | — | — | — | — |
Earnings Yield |
— | — | — | — | — | (27.01%) | — | — | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (20.21%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.54) | (1.23) | (1.29) | (2.14) | (2.81) | (5.79) | (13.02) | (21.91) | (26.80) | (0.47) |
Capex per Share |
0.00 | 0.00 | (0.68) | (0.68) | 0.00 | (0.03) | (0.18) | (0.47) | (0.97) | 0.00 |
Free Cash Flow per Share |
(0.54) | (1.23) | (1.97) | (2.82) | (2.81) | (5.82) | (13.20) | (22.38) | (27.78) | (0.47) |
Cash per Share |
1.03 | 1.83 | 2.41 | 3.75 | 7.11 | 24.57 | 8.08 | 22.77 | 17.61 | 0.66 |
Shareholders Equity per Share |
3.87 | 5.51 | 6.48 | 9.14 | 17.63 | 22.52 | 7.37 | 9.76 | 17.61 | 1.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.87 | 5.51 | 6.48 | 9.14 | 17.63 | 22.52 | 7.37 | 9.76 | 17.61 | 1.47 |
Free Cash Flow |
(8.87) | (14.90) | (18.80) | (20.94) | (17.23) | (14.39) | (23.27) | (25.32) | (10.12) | (5.20) |
Working Capital |
15.23 | 20.78 | 22.33 | 25.88 | 42.02 | 60.79 | 11.07 | 14.30 | 2.18 | 6.04 |
Capital Expenditures |
— | — | (6.46) | (5.03) | — | (0.07) | (0.32) | (0.53) | (0.35) | (1.93) |
Net Current Asset Value |
14.62 | 17.33 | 12.45 | 18.12 | 24.93 | 55.57 | 8.60 | 2.12 | (4.09) | 4.82 |
EV/EBIT |
— | — | — | — | — | 0.00 | — | — | — | — |
Capex to Sales |
— | — | 0.00 | 0.00 | — | 0.35 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | — | — | — | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.88 | 0.47 | 0.46 | 1.19 | 0.00 | 10.74 | 1.13 | 1.11 | 0.95 | 0.97 |
Cash ROIC |
(10.97%) | (16.79%) | (22.18%) | (21.85%) | (11.34%) | (12.36%) | (85.44%) | (66.35%) | (71.84%) | (21.09%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.24 | 0.27 | 0.75 | 1.82 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,170.33 | 1,151.48 | 1,925.44 | 916.09 | 55.17 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.07 | 0.42 | 0.76 | 0.68 | 0.54 | 0.54 | 0.87 | 0.89 | 0.37 | 0.14 |
Average Payables |
2.04 | 1.81 | 2.51 | 3.25 | 2.32 | 4.41 | 9.81 | 8.77 | 2.76 | 1.06 |
Average Assets |
69.32 | 72.65 | 76.21 | 103.87 | 95.54 | 42.66 | 29.87 | 27.40 | 18.50 | 19.60 |
Average Common Equity |
65.25 | 64.18 | 64.85 | 88.11 | 81.97 | 34.33 | 12.02 | 8.73 | 11.34 | 16.67 |
Columns are period end dates